b'Hematolymphoid Screening Panel - Flow CytometryClinical Information This panel not only provides evaluation and monitoring of The 10-color Hematolymphoid Screening Panel provides apatients with hematological malignancy but provides a wide comprehensive approach for evaluating bone marrow andarray of applications due to its comprehensive biomarker peripheral blood samples for the presence or absence ofselection.hematolymphoid malignancies. The panel characterizes and identifies all major white blood cell lineages and identifiesBiomarkers in the Screening Panelall major types of hematopoietic neoplasia. BiomarkerCD2, CD3, CD4, CD5, CD7, CD8, CD10, CD11b, CD13, CD14, selection follows the 2006 Bethesda Consensus 1forCD15, CD16, CD19, CD20, CD23, CD33, CD34, CD38, CD45, immunophenotypic analysis of hematolymphoid neoplasiaCD56, CD57, CD64, CD71, CD117, CD123, HLA-DR, Kappa, with additions chosen by our internal hematopathologistLambda, and TCR Gamma/Delta.based on recent literature including the 2017 WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 2-8 References1.BL Wood et al., Cytometry B Clin Cytom. 72:S14-S22 (2007).2.FE Craig et al., Blood. 111(8):3941-67 (2008). 3.BL Wood. Arch Pathol Lab Med. 130:680-90 (2006).4.SH Swerdlow et al., WHO Classification of Tumours, Revised 4th Edition, Volume 2 (2017) 5.CLSI H43: Clinical Flow Cytometric Analysis of Neoplastic Hematolymphoid Cells, 2nd Edition6.JJ Van Dongen et al., Leukemia. 26(9):1908-75 (2012).7.A Porwit and A Rajab. Int. Jnl. Lab. Hem., 37:133-143 (2015).8.Sheikholeslami et al., Methods in Molecular Biology.378. 53-63. 10.1007/978-1-59745-323-3_4 (2007).58'